This unique new book uses a series of focussed questions, comprehensive literature evaluations and structured grades of recommendation to provide evidence for the treatment of hematological disorders, both malignant and benign. With contributions from leading international experts who have a real understanding of evidence-based medicine the book provides comprehensive reviews accompanied by clinical commentaries and recommendations on the best treatment regimes to adopt for individual patients. The book is split into two sections: the first examines the methodology underlying evidence based practice, and the second concentrates on the clinical practice of hematology, providing current abest evidencea to guide practice in a series of well-defined clinical situations. This clinical reference is an invaluable source of evidence-based information distilled into guidance for clinical practice which will be welcomed by practitioners, trainees and associated health professionals.Reference No. of patients INR studied Treatment Outcome Results Pengo (42) 23 agt;5 A:WithholdwarfarinA1 day B:2mgvitKPO INR alt;5 at 24 and 48 ... B: 6a10 C, D: agt;10 A: 2.5 mg vit K PO B: 0.5 mg vit K iv C: 5 mg vit K PO D: 1 mg vit K iv INR at 24 and 48 hours IV vit K caused a faster drop in the INR. ... FFP and PCCs are both plasma-derived products used for the urgent reversal of VKA coagulopathy.
|Author||:||Mark A. Crowther, Jeffrey Ginsberg, Holger Schünemann, Ralph M. Meyer, Richard Lottenberg|
|Publisher||:||John Wiley & Sons - 2009-01-30|